iiinova — where your digital self keeps evolving

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 31/05/2025

VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social @oncoalert.bsky.social #ASCO25

1103

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 31/05/2025

Reflex cDNA-methylation multi-cancer early detection (MCED) test achieved meaningful per-cancer intrinsic accuracy & per-tissue of origin PPV across mult cancer types evaluated in at-risk indiv w/obesity. #ASCO25 @oncoalert.bsky.social

053

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 30/05/2025

The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

172

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 30/05/2025

Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged. 27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25 @oncoalert.bsky.social

082

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 30/05/2025

AI-assisted training changed HER-2 low, ultra low, null classification in this analysis by Marina DeBrot et al #ASCO25

051

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 30/05/2025

Kicking off breast sessions #ASCO25 with the data that Black patients with breast cancer continue to have worse overall survival in the modern-HER2 era. Adjusted HR 1.28 @oncoalert.bsky.social

030

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 24/05/2025

Join me & Maryam Lustberg at #ASCO25 at #OncForum2025 to discuss ADCs, sequencing, HER2 low/ultra-low, biomarkers, and “right-sizing” early stage disease Saturday June 1 at 7:15- 7:45 PM Duneyrr Fermenta & Brewery 2337 S. Michigan Ave. Register now! app.smartsheet.com/b/form/7e557...

031

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 16/05/2025

Honored and humbled to be awarded the 2025 E. Grey Diamond Take Wing Award, my school’s highest alumni honor. Thank you, Dean Norbash, my amazing family, members of the awards committee— I am proud to embody the spirit of UMKC SOM in all that I do.

010

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 10/05/2025

In <1 minute, use @ascocancer.bsky.social link to #ProtectMedicaid. Maybe you think it isn’t about you—but sometimes patients w/cancer lose their job, insurance is tied to employment, then suddenly—Medicaid is about them. Urge members of congress to safeguard Medicaid ➡️brnw.ch/21wSxkd

030

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 16/04/2025

I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation

0101

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 08/04/2025

An honor to meet w/Rep.Magaziner staff, Raisa Majid with Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages. @ascocancer.bsky.social

171

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 08/04/2025

I am joining over 150 oncologists this week at the #ASCOAdvocacySummit in Washington, D.C. to urge Congress to help address existing #drugshortages and prevent future shortages of lifesaving and life-prolonging cancer drugs. @ascocancer.bsky.social

0103

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 08/04/2025

Had delightful meeting w/Sen. Whitehouse staffer Joe Page w/Drs Mega & Strenger to discuss key #ASCOAdvocacySummit key asks incld consistent funding for the NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages @ascocancer.bsky.social

031

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 08/04/2025

ASCO CEO Cliff Hudis joined #RhodeIsland’s #ASCOAdvocacySummit delegates Drs.Mega, Strenger & I meeting w/Senator Reed Our key asks incld consistent funding for NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to CareAct; partnering on a Solution to End DrugShortages @ascocancer.bsky.social

021

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 08/04/2025

An honor to meet w/ #RepGabeAmo this AM w/Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Comprehensive Solution to End Drug Shortages. @ascocancer.bsky.social

021

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 07/04/2025

#RhodeIsland’s own Anthony Mega engaging with the #ASCOAdvocacySummit team around ways oncology clinicians can advocate for prior authorization reform thru Improving Seniors Timely Access to Care Act. #PriorAuth @ascocancer.bsky.social @weldeiry.bsky.social

031

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 07/04/2025

Hot tips from #ASCOAdvocacySummit #ASCOAdvocacy: A Media Interview (or high profile meeting) is the WRONG TIME for an original thought. Stay on message! Come prepared. Preach! 🙌🏻 🗣️ @ascocancer.bsky.social @lymphomadoc.bsky.social @ishwaria.bsky.social

062

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 06/04/2025

Thanks, @ASCO for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the #oncology community. You can be an Advocacy Champion too by getting involved today: asco.org/actnetwork #ASCOAdvocacySummit

0121

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 03/04/2025

Identifying surrogate endpoints as valid, reliable primary endpoints is key to advancing cancer care. Partnered on this real-world data analysis demonstrating very strong, positive correlation between iDFS and OS @acsjournalcancer.bsky.social acsjournals.onlinelibrary.wiley.com/doi/full/10....

010

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 14/03/2025

Looking to include more advocate partners in your work, or train as an advocate yourself? @TanjaSpanic @EuropaDonnaSLO includes this list of for places to start. #SGBCC2025

021

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 14/03/2025

Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025

053

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 14/03/2025

May I ask more about your experience? There was an interesting presentation yesterday (I didn’t post) on the complicated, limited, conflicting data around patient satisfaction w/breast conservative vs mastectomy—and the variables that contribute which are difficult to account for scientifically

100

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 14/03/2025

Christian Singer presents alternatives to bilateral mastectomy for risk reduction in women with BRCA pathogenic variant. He cites benefits to effective screening (MRI), BSO, tamoxifen, and lifestyle modifications (specifically exercise & weight loss) as strategies. #SGBCC2025 #brca

282

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Beyond ChatGPT and digital pathology algorithms, @jnkt.bsky.social reviews current and future states for deep learning artificial intelligence in breast oncology #SGBCC2025

1144

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Marleen Kok @marleenkok.bsky.social had the difficult task of discussing the role of IO in HR+ breast cancer—she focused on ER-low disease, and suggests that we treat as TNBC. #SGBCC2025

051

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Fantastic talk answering the question “Which tumors warrant adjuvant CDK4/6 inhibitors?” Here are the 🔑 take aways from @AngieDemichele (which I was really thankful for, as I otherwise took photos of every slide 😅) #SGBCC2025

041

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Pru Francis says that determining ET options for premenopausal women with breast cancer is the hardest decision we make in medical oncology. #SGBCC2025

020

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

After reviewing the data, @kalinskykevin.bsky.social just cuts to the chase and answers the question—which ER+ tumors still require chemotherapy #SGBCC2025

021

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

David Cameron offers cautious approach to implementing CDK4/6 inhibitors after starting w historic perspective that concerns thrown at adjuvant tamoxifen & adjAI are the same concerns voiced today for CDK4/6i. Ends with “Fools rush in where angels fear to tread” #SGBCC2025

041

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

🗳️Ultimately, the audience at #SGBCC2025 votes AGAINST (52% vs 46%) radiation for all patients with node-positive breast cancer and low volume nodal disease

042

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

While discussing the PROs RE: mastectomy vs. breast conserving surgery, Jana de Boniface highlights how deeply the degree of patient engagement and choice impact the satisfaction with outcome—which is often an unmeasured variable. #SGBCC2025

081

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Daniela Kauer-Dorner masterfully reviews the data around tailored options for radiotherapy as well as ongoing trials to further resolve questions in the field. #SGBCC2025

021

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Dr. Mafalda Oliveira had the challenge of answering “Pyrrhic victory? Are newer approaches causing more harm than good?” and rose to the challenge, addressing the toxicity and long-lasting impacts of therapy. #SGBCC2025

031

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Issuing a call to action for incorporation of biomarkers in clinical trial design, Mafalda Oliveira speaks to the value of stakeholder engagement in trial design. #SGBCC2025

052

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

Focusing on patients at a low risk (emphasis mine) of recurrence, Charlotte Coles reviews the options to optimize therapy. ⚖️ Lots of mix-and-match options that should lend to divergence or freedom of choice on the final consensus panel. #SGBCC2025

020

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 13/03/2025

For those following along at home—a fantastic interdisciplinary lineup on the schedule today. ☢️🔪💊🤖🩻 #SGBCC2025 #oncsky #bcsm

010

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/03/2025

HER2DX is the test on everyone’s lips, here from Nadia Harbeck slides. Hoping to see Master of Ceremonies @drhburstein.bsky.social grill down during consensus—is it ready for prime time? In which HER2+ populations? If not, what data is needed to flip the switch? #SGBCC2025

001

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/03/2025

Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #SGBCC2025

041

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · 12/03/2025

The next several days marks the St. Gallen’s International Breast Cancer conference culminating in the early breast cancer consensus panel. Excited to finally be on site! #sgbcc2025